Helena Granstam-Björneklett

Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Heikki Joensuu, Judith Fraser, Hans Wildiers et al. · JAMA Oncology · 2018 · 149 citations · Full text

Medicine, Oncology, Pharmacology +17

NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapy

Fariba Mozaffari, C. Lindemalm, A Choudhury et al. · British Journal of Cancer · 2007 · 86 citations · Full text

Life Sciences, Immunology, Oncology +17

Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study

Fariba Mozaffari, C. Lindemalm, Aniruddha Choudhury et al. · Cancer Immunology Immunotherapy · 2008 · 36 citations · Full text

Medicine, Immunology, Oncology +17

Immune response, depression and fatigue in relation to support intervention in mammary cancer patients

C. Lindemalm, Fariba Mozaffari, Aniruddha Choudhury et al. · Supportive Care in Cancer · 2007 · 17 citations

Medicine, Immunology, Oncology +14

Abstract GS3-04: A randomized phase III study of adjuvant trastuzumab for a duration of 9 weeks versus 1 year, combined with adjuvant taxane-anthracycline chemotherapy, for early HER2-positive breast cancer (the SOLD study)

Heikki Joensuu, Jennifer A. Fraser, Hans Wildiers et al. · Cancer Research · 2018 · 12 citations

Medicine, Oncology, Pharmacology +17